References
- CiprandiGBuscagliaSCerquetiPMCanonicaGWDrug treatment of allergic conjunctivitis. A review of the evidenceDrugs1992431541761372215
- UchioEKimuraRMigitaHKozawaMKadonosonoKDemographic aspects of allergic ocular diseases and evaluation of new criteria for clinical assessment of ocular allergyGraefes Arch Clin Exp Ophthalmol200824629129617940788
- AbelsonMBSmithLChapinMOcular allergic disease: Mechanisms, disease sub-types, treatmentOcul Surf2003112714917075644
- AijazSBaldaMSMatterKKwangWJTight junctions: Molecular architecture and functionInternational Review of CytologyNew York, NYAcademic Press2006
- HughesJLLackiePMWilsonSJChurchMKMcGillJIReduced structural proteins in the conjunctival epithelium in allergic eye diseaseAllergy2006611268127417002701
- WanHWintonHLSoellerCThe transmembrane protein occludin of epithelial tight junctions is a functional target for serine peptidases from faecal pellets of Dermatophagoides pteronyssinusClin Exp Allergy20013127929411251630
- RunswickSMitchellTDaviesPRobinsonCGarrodDRPollen proteolytic enzymes degrade tight junctionsRespirology20071283484217986111
- AbramowiczMDrugs for allergic disordersMedical Letter Treatment Guidelines20108918
- RubensteinNMGuanYWooPLFirestoneGLGlucocorticoid down-regulation of RhoA is required for the steroid-induced organization of the junctional complex and tight junction formation in rat mammary epithelial tumor cellsJ Biol Chem2003278103531036012525486
- SalterMBiggadikeKMatthewsJLPharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory diseaseAm J Physiol Lung Cell Mol Physiol2003293L660L66717575011
- BohetsHMcGowanCMannensGSchroederNEdwards-SwansonKShapiroAClinical pharmacology of alcaftadine, a novel antihistamine for the prevention of allergic conjunctivitis2011J Ocul Pharm Ther In press.
- Gallois-BernosAThurmondRAlcaftadine, a new class of antihistamine with combined antagonist activity at H1, H2, and H4 histamine receptors Personal communication.
- OhmoriKHayashiKKaiseTPharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drugJpn J Pharmacol20028837939712046981
- FukuishiNMatsuhisaMShimonoTInhibitory effect of olopatadine on antigen-induced eosinophil infiltration and the LFA-1 and Mac-1 expression in eosinophilsJpn J Pharmacol20028846346612046991
- MiyazakiDNakamuraTOhbayashiMAblation of type I hypersensitivity in experimental allergic conjunctivitis by eotaxin-1/CCR3 blockadeInt Immunol20092118720119147836
- LingPNgoKNguyenSHistamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule up regulationBr J Pharmacol200414216117115131002
- BrockmanHLMomsenMMKnudtsonJRMillerSTGraffGYanniJMInteractions of olopatadine and selected antihistamines with model and natural membranesOcul Immunol Inflamm20031124726814704897
- TeradaNHamanoNNumataTKonnoATransepithelial migration of activated eosinophils induces a decrease of E-cadherin expression in cultured human nasal epithelial cellsClin Exp Allergy20003080781710848899
- KobayashiNDezawaMNagataHYuasaSKonnoAImmunohistochemical study of E-cadherin and ZO1 in allergic nasal epithelium of the guinea pigInt Arch Allergy Immunol19981161962059693267